



THE 2nd INTERNATIONAL MULTIDISCIPLINARY ANAL CANCER CONFERENCE

9-10 November, 2023

Centro Congressi Europa

Sala Italia Largo Francesco Vito 1

**Catholic University of Sacred Heart -
Policlinico Agostino Gemelli, Rome, Italy**

The 2nd International Multidisciplinary Anal Cancer Conference

**9-10 November, 2023 at Catholic University of Sacred Heart - Policlinico Agostino
Gemelli, Rome, Italy**

Program

Thursday, 9 November 2023

08:30-09:00 Arrival and registration

09:00-09:05 Welcome

Karen-Lise Garm Spindler, Aarhus, Denmark and Maria Antonietta Gambacorta, Rome, Italy

09:05-09:25 Keynote lecture; Humanistic Guided Oncology

Vincenzo Valentini, Rome, Italy

09:25-09:40 Inequalities in anal cancer treatment – how can we contribute?

Eva Segelov, Bern, Switzerland

09:40-10:00 Panel discussion with patient representatives

Moderated by Pierfrancesco Franco, Novara, Italy and Eva Segelov, Bern, Switzerland

10:00-13:00 Session 1: Clinical Trials status, update, and perspectives for collaboration

Chairs: Marianne Guren, Oslo, Norway and David Sebag-Montefiore, Leeds, UK

10:00-10:15 Clinical trials for anal cancer - what have we learnt and what can we do better?

David Sebag-Montefiore, Leeds, UK

10:15-10:30 Evaluating immunotherapy in the curative treatment of anal cancer

Rob Glynne-Jones, London, UK

10:30-11:00 Coffee

11:00-11:15 Defining new standards of care for advanced disease

Sheela Rao, Sutton, UK

11:15-11:30 Future novel agents on the horizon for anal cancer

Dirk Arnold, Hamburg, Germany

11:30-12:15 Oxford debate: this house believes that neo-adjuvant chemotherapy is a useful treatment strategy for patients with non-metastatic anal cancer

Chair: David Sebag-Montefiore, Leeds, UK

Pro - Veronique Vendrely, Bordeaux, France

Con - Rob Glynn-Jones, London, UK

12:15-13:00 Proffered papers

Chairs: Sheela Rao, Sutton, UK and Dirk Arnold, Hamburg, Germany

5 min. presentation – 2 min. discussion

1. Equity challenges in research: Unveiling disparities within Anal Cancer Trials
Daniëlle Verschoor, Bern, Switzerland
2. Standard vs dose reduced chemoradiotherapy in anal cancer: Updated Phase II results of the PLATO-ACT4 RCT ISRCTN88455282
Alexandra Gilbert, Leeds, United Kingdom
3. Role of concomitant chemotherapy in management of early stage squamous cell carcinoma of the anal canal: ancillary study of the national FFCD-ANABASE cohort.
TBC: Chloe Buchalet, Montpellier, France
4. Heterogeneity in trial design for radiotherapy-immunotherapy combination studies in squamous cell anal cancer - are we making the same mistakes again?
Robert Samuel, Leeds, United Kingdom
5. GOBLET: A phase 1/2 multiple indication study in advanced gastrointestinal cancers treated with pelareorep and atezolizumab – preliminary safety and efficacy results in second-line or later unresectable anal carcinoma
Dirk Arnold, Hamburg, Germany
6. Real-life status on efficacy and outcome after treatment with pembrolizumab in patients with advanced anal cancer in Denmark
Christian Andreas Hvid, AUH, Denmark

13:00-14:00 Lunch

14:00-18:00 Session 2: Biology, Basic and translational science

Chairs: Duncan Gilbert, London, UK and Karen-Lise Garm Spindler, Aarhus, Denmark

14:00-14:15 IRCI anal cancer translational science group work

Duncan Gilbert, London, UK

14:15-14:30 Hypoxia in SCC Anal cancer, results and perspectives

Karen Wind, Aarhus, Denmark

14:30-14:45 PDX generations, and potential use for collaboration

Morten Busk, Aarhus, Denmark

14:45-15:00 Microbiome

Antonio Gasbarrini, Rome, Italy

15:00-15:15 Imaging biomarkers in anal cancer
TBC

15:15-16:30 What is the biological difference between HPV positive and negative disease?
Andrew McDonald, Leeds, UK

15:30-15:45 pHPV studies in SCC – update from pan-scam
Karen-Lise Garm Spindler, Aarhus, Denmark

15:45-16:15 Coffee

16.15- 17.15 Proffered papers flash talks

Chairs: Per Nilsson, Stockholm, Sweden and Anders Johnsson, Lund, Sweden

1. Expression of cancer stem cell markers as potential biomarker in squamous cell carcinoma of the anus
Karen Wind, Aarhus, Denmark
2. Circulating markers of disease in locally advanced anal cancer patients treated within the PLATO trial.
Duncan Gilbert, Brighton, UK
3. Prognostic value of 18F-FDG PET/CT assessment in anal carcinoma in patients from FFCD-ANABASE cohort
Virginie Combet-Curt, Bordeaux, France
4. Efficacy and toxicity of (chemo)radiotherapy in HIV-positive patients with squamous cell anal cancer, a subgroup analysis of the national multicentric cohort ANABASE
Florence Huguet, Paris, France
5. International validation of the EORTC QLQ-ANL27, an anal cancer-specific health-related quality of life questionnaire
Samantha Sodergren, Southampton, United Kingdom
6. SEXual QUality Of life In Anal cancer (SEQUOIA): : A prospective longitudinal study
Claire Lemanski, Montpellier, France
7. Late gynecologic toxicity after radiotherapy for anal cancer.
Elizabeth Møller Hedegaard, Aarhus, Denmark
8. Bowel delineation methods and dosimetric predictors of acute and late diarrhea in radiotherapy for anal cancer
Katrine Smedegaard Storm, Copenhagen, Denmark

Gemelli

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Università Cattolica del Sacro Cuore



ART
Advanced Radiation
Therapy



UNIVERSITÀ
CATTOLICA
del Sacro Cuore

17:15-18:00 Discussion topics

Moderated by Duncan Gilbert, London, UK and Karen-Lise Garm Spindler, Aarhus, Denmark

18:00-19:00 Poster session including drinks and snacks

Chairs: Anders Johnson, Lund, Sweden, Marianne Guren, Oslo, Norway, and Per Nilsson, Stockholm, Sweden

19:30- Conference dinner

Endorsed by⁷
ESTRO



Associazione Italiana
Radioterapia e Oncologia clinica



Friday, 10 November 2023

09:00-10:15 Session 3: Improved radiotherapy

Chairs: Pierfrancesco Franco, Novara, Italy and Maria Antonietta Gambacorta, Rome, Italy

09:00-09:15 Where are the limitations with current IMRT based therapy?

Pierfrancesco Franco, Novara, Italy

09:15-09:30 Optimal imaging assessment and new diagnostic tools

TBC

09:30-09:45 Risk adapted target definition

Martin Nilsson, Lund, Sweden

09:45-10:00 AtomCat for all? Update for utility?

Ane Appelt, Leeds, UK

10:00-10:15 Potential of Ethos therapy

Eva Serup-Hansen, Herlev, Denmark

10:15-10:30 Potential of the MR-linac in anal cancer

Giuditta Chiloire, Rome, Italy

10:30-11:00 Coffee

11:00-12:00 Session 3: Improved radiotherapy (continued)

11:00-11:15 Role of brachytherapy in anal cancer

Bruno Fionda, Rome, Italy

11:15-11:30 Proton therapy in anal cancer

Camilla Kronborg, Aarhus, Denmark

11:30-11:45 Management of radiation proctitis

Carlo Ratto, Rome, Italy

11:45-12:45 Lunch

12:45-13:30 Proffered papers

Chair: Stefania Manfrida, Rome, Italy and Veronique Vendrely, Bordeaux, France

1. De-escalation of elective lymph node volume in early anal cancer treated with chemoradiotherapy – a Swedish cohort study
Sofia Heyman, Gothenburg, Sweden
2. Bonesparing radiotherapy for anal cancer. Plan comparison in the DACG II trial
Camilla Kronborg, Aarhus, Denmark

3. HIT-ART: Highly Tailored Anal cancer MRI guided interventional RadioTherapy (brachytherapy) study: results of 10-year experience
Bruno Fionda, Rome, Italy
4. Electron beam radiotherapy for the management of perianal squamous cell carcinoma
Lars Fokdal, Vejle, Denmark
5. Optimal posttreatment time for magnetic resonance imaging (MRI) response evaluation in squamous cell carcinoma of the anus (SCCA)
Bettina Andrea Hanekamp, Oslo, Norway
6. Impact of time from diagnosis to start of radiotherapy in anal cancer
Jakob Hallström, Lund, Sweden

13:30-15:00 IMACC Discussion

Facilitation of international collaboration, focus and research on anal cancer

Moderated by Dirk Arnold, Hamburg, Germany and David Sebag-Montefiore, Leeds, UK

This program may be subject to minor changes.

With the unconditional contribution of

